Skip to Main Content

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a mid-stage clinical trial.

Taken by patients within one hour of a swelling attack, the KalVista pill, called KVD900, relieved symptoms quickly so that only 15% of attacks required the use of rescue medications within 12 hours compared with 30% of the attacks treated with a placebo pill. The difference was statistically significant, meeting the primary goal of the study, the company said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!